Swimming Against The Tide, Lannett May Wipe Out Shareholders With Refinancing

US-Based Player Also Fails To Pay Interest Due On Unsecured Convertible Note

Lannett is weighing major surgery for its balance sheet as it continues to feel the pain of its eye watering and unsustainable debt load.

Hurca/Shutterstock.com
• Source: Shutterstock

Saddled with debt and with market forces weighing heavily on its operations, Lannett is eyeing a potential recapitalization or restructuring of its balance sheet. The company admits that its shareholders might be wiped out under any such deal, for which it expects to reach an agreement with its key secured creditors “in the near term.”

The Philadelphia-based firm outlined that the potential for a restructuring had been triggered by continued competitive pressures on its portfolio,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

Nexus Faces Five Year Wait On Injectable Minocycline

Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

test

uygukgigo

 
• By 

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.